Covidien Launches Next-Generation Trellis Peripheral Infusion System

Treatment for DVT redesigned to improve thrombus isolation, lytic drug delivery, removal of blood clot


July 30, 2014

Covidien announced's next-generation Trellis peripheral infusion system is a pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to post-thrombotic syndrome (PTS). This latest Trellis system has been optimized to enhance drug delivery and the removal of the dissolved clot.

PTS is a long-term effect of deep vein thrombosis (DVT), a condition where a clot develops in one of the body’s deep veins above the knee. PTS develops when a DVT interferes with the blood flow returning from the leg back to the heart. It can cause lower leg pain and swelling, and can damage the valves in the veins that normally stop blood from flowing backwards down the leg. PTS occurs in almost half of patients within two years after DVT, and up to 33 percent of patients with PTS develop ulcers and skin deterioration.

The Trellis system provides a way for physicians to dissolve acute thrombus and intervene on DVT before it advances to PTS. The system is comprised of an over-the-wire catheter with two occlusive balloons to close off the treatment area and block drug release to other areas of the body; an infusion zone to deliver the lytic drug; and an oscillation drive unit that disperses the drug to dissolve the clot. The updated Trellis system features enhanced drug delivery and increased amplitude of the dispersion wire to better distribute the drug throughout the clot. Additionally, the new system features a larger aspiration window than the previous version, which allows for better removal of the drug and the dissolved clot.

The Trellis peripheral infusion system is currently available in the United States, Europe and Canada as of July 2014.

For more information: